EU MDR vs FDA QMSR
The two regimes a device sold on both sides of the Atlantic must clear.
What a comparison is not
A comparison is SPEQ’s reading of how two published documents differ. Neither is the right answer, it is not a determination of which applies to you, and neither is summarised in a way that replaces reading it.
The EU Medical Device Regulation (MDR, 2017/745) is the full market-access regime for devices in the EU — classification, conformity assessment, clinical evidence, notified bodies, and post-market surveillance. The FDA QMSR is the US device quality-system regulation (the ISO 13485-based rewrite of 21 CFR 820). MDR is a whole regulatory framework; QMSR is specifically the quality-system layer — so they are not like-for-like.
| ASPECT | EU MDR | FDA QMSR |
|---|---|---|
| Scope | Entire EU market-access regime for devices | The US device quality-system requirements only |
| Conformity route | Notified-body conformity assessment + CE marking | FDA clearance/approval pathway is separate (510(k)/PMA/De Novo) |
| Clinical evidence | Detailed clinical evaluation + PMCF requirements | Handled via the premarket submission, not the QMSR itself |
| QMS basis | QMS required (aligns with ISO 13485) | Incorporates ISO 13485:2016 by reference |
| Post-market | Extensive PMS, vigilance, PSUR, EUDAMED | MDR reporting, complaint handling under QMSR + 803 |
| UDI / traceability | EU UDI + EUDAMED registration | US UDI (21 CFR 830) |
Work to EU MDR to place a device on the EU market — it is a complete regulatory framework (classification, notified body, clinical, PMS, EUDAMED), not just a quality system.
Work to FDA QMSR for the US quality-system requirements — but remember the QMSR is only the quality-system piece; US market entry also requires the appropriate FDA premarket pathway.
These are not the same kind of thing. EU MDR is a full market-access regulation; the FDA QMSR is the quality-system regulation, with US market entry handled separately by 510(k)/PMA/De Novo. Because both the MDR QMS expectation and the QMSR align to ISO 13485:2016, a 13485-built quality system is the shared backbone — but MDR adds clinical, notified-body, and EUDAMED obligations that have no QMSR analogue.
EU MDR vs FDA QMSR: frequently asked questions
Common questions on how EU MDR and FDA QMSR differ and when each applies.
Is EU MDR the European equivalent of the FDA QMSR?
No — they are different scopes. The QMSR is the US device quality-system regulation. Its nearest EU counterpart is the ISO 13485 QMS expectation within MDR, not the whole MDR, which also covers classification, conformity assessment, clinical evidence, and post-market surveillance.
Does an ISO 13485 QMS satisfy both?
It is the shared backbone. The QMSR incorporates ISO 13485:2016 by reference, and MDR expects an ISO 13485-aligned QMS. But each adds region-specific obligations (US UDI and MDR reporting under QMSR; EU UDI, EUDAMED, clinical evaluation, and PMCF under MDR).
What replaces CE marking in the US?
Nothing directly — CE marking reflects EU conformity assessment. US market entry is via FDA clearance (510(k)), approval (PMA), or De Novo classification, which are premarket pathways separate from the QMSR quality-system requirements.
When did each take effect?
EU MDR applied from 26 May 2021 (with staggered transition provisions for legacy devices). The FDA QMSR final rule was published in Feb 2024 and becomes enforceable on 2 February 2026, replacing the prior Quality System Regulation.